BR112015032542A2 - peptídeos e peptídeos miméticos em tratamentos e usos de combinação para subpopulações de pacientes com câncer - Google Patents
peptídeos e peptídeos miméticos em tratamentos e usos de combinação para subpopulações de pacientes com câncerInfo
- Publication number
- BR112015032542A2 BR112015032542A2 BR112015032542A BR112015032542A BR112015032542A2 BR 112015032542 A2 BR112015032542 A2 BR 112015032542A2 BR 112015032542 A BR112015032542 A BR 112015032542A BR 112015032542 A BR112015032542 A BR 112015032542A BR 112015032542 A2 BR112015032542 A2 BR 112015032542A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptides
- subpopulations
- cancer patients
- combination treatments
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
esta invenção fornece compostos incluindo peptídeos e peptidomiméticos, que podem ser utilizados para tratar distúrbios pro-liferativos de células, tais como aqueles associados às células de tu-mores benignos e malignos. embora a invenção não esteja limitada a qualquer mecanismo particular, os compostos da invenção parecem funcionar, pelo menos em parte, pela inibição da barreira g2 do ciclo celular. assim, os compostos da invenção podem ser utilizados para inibir o crescimento celular por si só ou ser usados em combinação com um tratamento de ácido nucleico prejudicial para inibir o crescimento celular.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361838777P | 2013-06-24 | 2013-06-24 | |
| PCT/IB2014/001579 WO2014207556A1 (en) | 2013-06-24 | 2014-06-24 | Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015032542A2 true BR112015032542A2 (pt) | 2017-07-25 |
Family
ID=52141164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015032542A BR112015032542A2 (pt) | 2013-06-24 | 2014-06-24 | peptídeos e peptídeos miméticos em tratamentos e usos de combinação para subpopulações de pacientes com câncer |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9221872B2 (pt) |
| EP (1) | EP3013351B1 (pt) |
| JP (1) | JP6401255B2 (pt) |
| KR (1) | KR102247493B1 (pt) |
| CN (1) | CN105324121A (pt) |
| AU (1) | AU2014300713B2 (pt) |
| BR (1) | BR112015032542A2 (pt) |
| CA (1) | CA2916136C (pt) |
| CL (1) | CL2015003704A1 (pt) |
| CY (1) | CY1122523T1 (pt) |
| DK (1) | DK3013351T3 (pt) |
| ES (1) | ES2765300T3 (pt) |
| HK (1) | HK1219905A1 (pt) |
| HR (1) | HRP20192264T1 (pt) |
| HU (1) | HUE046873T2 (pt) |
| IL (1) | IL243266B (pt) |
| LT (1) | LT3013351T (pt) |
| MX (1) | MX366341B (pt) |
| MY (1) | MY182232A (pt) |
| PH (1) | PH12015502855A1 (pt) |
| PL (1) | PL3013351T3 (pt) |
| PT (1) | PT3013351T (pt) |
| RS (1) | RS60180B1 (pt) |
| RU (1) | RU2732440C2 (pt) |
| SG (1) | SG11201510490VA (pt) |
| SI (1) | SI3013351T1 (pt) |
| WO (1) | WO2014207556A1 (pt) |
| ZA (1) | ZA201600089B (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| EP2968443B1 (en) | 2013-03-15 | 2021-09-29 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| LT3143037T (lt) | 2014-05-16 | 2021-10-11 | Protagonist Therapeutics, Inc. | Alfa4beta7 integrino tioeterio peptidų antagonistaii |
| CN113563423A (zh) | 2014-07-17 | 2021-10-29 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
| EP3201217A4 (en) | 2014-10-01 | 2018-07-18 | Protagonist Therapeutics Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
| US9809623B2 (en) | 2014-10-01 | 2017-11-07 | Protagonist Therapeutics, Inc. | α4β7 peptide monomer and dimer antagonists |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| TWI805542B (zh) * | 2015-10-23 | 2023-06-21 | 日商坎巴斯有限公司 | 用於癌症治療之肽及擬肽與ｔ細胞活化劑及／或查核點抑制劑之組合 |
| WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| CN109195618A (zh) | 2016-03-23 | 2019-01-11 | 领导医疗有限公司 | 用于合成α4β7肽拮抗剂的方法 |
| CN109563144B (zh) | 2016-06-01 | 2023-03-28 | 雅斯娜 | 化合物 |
| US10278957B2 (en) | 2017-09-11 | 2019-05-07 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
| CA3089868A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| MX2022000397A (es) | 2019-07-10 | 2022-04-25 | Protagonist Therapeutics Inc | Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
| WO2021146454A1 (en) | 2020-01-15 | 2021-07-22 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| CR20220332A (es) | 2020-01-15 | 2022-11-28 | Janssen Biotech Inc | Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias |
| PE20240631A1 (es) | 2020-11-20 | 2024-03-26 | Janssen Pharmaceutica Nv | Composiciones de inhibidores peptidicos del receptor de interleucina-23 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1483290T3 (da) * | 2002-01-17 | 2008-11-03 | Takeda Pharmaceutical | Peptider og peptidmimetika, der har anti-proliferativ aktivitet og/eller forstærker nukleinsyrebeskadigende midler eller behandlinger |
| US7148349B2 (en) * | 2002-10-31 | 2006-12-12 | Metabasis Therapeutics, Inc. | Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs |
| US7125842B2 (en) * | 2003-04-07 | 2006-10-24 | Canbas Co. Ltd. | Anti-fungal compounds and methods of use |
| JP4705567B2 (ja) * | 2003-06-25 | 2011-06-22 | 株式会社 キャンバス | 免疫調整活性、抗炎症活性、および抗ウイルス活性を有するペプチドおよびペプチド模倣物 |
| US20100112089A1 (en) | 2008-05-14 | 2010-05-06 | Takeda Pharmaceutical Company Limited | Peptide compound and use thereof |
-
2014
- 2014-06-24 ES ES14818523T patent/ES2765300T3/es active Active
- 2014-06-24 PL PL14818523T patent/PL3013351T3/pl unknown
- 2014-06-24 MY MYPI2015704731A patent/MY182232A/en unknown
- 2014-06-24 MX MX2015017609A patent/MX366341B/es active IP Right Grant
- 2014-06-24 CA CA2916136A patent/CA2916136C/en active Active
- 2014-06-24 PT PT148185234T patent/PT3013351T/pt unknown
- 2014-06-24 SG SG11201510490VA patent/SG11201510490VA/en unknown
- 2014-06-24 HU HUE14818523A patent/HUE046873T2/hu unknown
- 2014-06-24 KR KR1020157036784A patent/KR102247493B1/ko active IP Right Grant
- 2014-06-24 RS RS20191687A patent/RS60180B1/sr unknown
- 2014-06-24 RU RU2016101718A patent/RU2732440C2/ru active
- 2014-06-24 CN CN201480035471.4A patent/CN105324121A/zh active Pending
- 2014-06-24 SI SI201431451T patent/SI3013351T1/sl unknown
- 2014-06-24 DK DK14818523.4T patent/DK3013351T3/da active
- 2014-06-24 WO PCT/IB2014/001579 patent/WO2014207556A1/en active Application Filing
- 2014-06-24 US US14/313,264 patent/US9221872B2/en active Active
- 2014-06-24 BR BR112015032542A patent/BR112015032542A2/pt not_active Application Discontinuation
- 2014-06-24 LT LTEP14818523.4T patent/LT3013351T/lt unknown
- 2014-06-24 EP EP14818523.4A patent/EP3013351B1/en active Active
- 2014-06-24 AU AU2014300713A patent/AU2014300713B2/en active Active
- 2014-06-24 JP JP2016520755A patent/JP6401255B2/ja active Active
-
2015
- 2015-12-21 IL IL24326615A patent/IL243266B/en active IP Right Grant
- 2015-12-22 CL CL2015003704A patent/CL2015003704A1/es unknown
- 2015-12-22 PH PH12015502855A patent/PH12015502855A1/en unknown
-
2016
- 2016-01-06 ZA ZA2016/00089A patent/ZA201600089B/en unknown
- 2016-07-12 HK HK16108103.9A patent/HK1219905A1/zh unknown
-
2019
- 2019-12-17 HR HRP20192264TT patent/HRP20192264T1/hr unknown
- 2019-12-23 CY CY20191101352T patent/CY1122523T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015032542A2 (pt) | peptídeos e peptídeos miméticos em tratamentos e usos de combinação para subpopulações de pacientes com câncer | |
| BR112018008179A2 (pt) | peptídeos e peptidomiméticos em combinação com agentes de ativos de células t e/ou agentes de inibição de ponto de verificação para tratamento de câncer | |
| BR112018070163A2 (pt) | compostos de aminopurina substituída, composições e métodos de tratamento | |
| BR112017022845A2 (pt) | neoepítopos de câncer | |
| BR112019021822A2 (pt) | Terapia de combinação | |
| ECSP15042895A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| CL2017001459A1 (es) | Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología | |
| MX2019011061A (es) | Compuestos útiles en el tratamiento o prevención de un trastorno mediado por la proteína arginina metil-transferasa 5 (prmt5). | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| BR112015007184A2 (pt) | combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer | |
| BR112015029386A2 (pt) | uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer | |
| BR112017006464A2 (pt) | bloqueio de cd73 | |
| BR112018070161A2 (pt) | moduladores de receptores de estrogênio | |
| BR112015028845A2 (pt) | compostos para a modulação da quinase e indicações da mesma | |
| EA201792509A1 (ru) | Лечение рака | |
| BR112012005970A2 (pt) | moduladores tricíclicos de proteína quinase | |
| CL2021001260A1 (es) | Anticuerpos anti-sirpa humanizados | |
| ECSP22055515A (es) | Compuestos y métodos para la degradación dirigida del receptor de andrógenos | |
| BR112017023517A2 (pt) | anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20 | |
| BR112017008045A2 (pt) | compostos como inibidores de nik | |
| BR112017007704A2 (pt) | derivados de pirazolopirimidina como inibidores de nik | |
| BR112017007715A2 (pt) | derivados de tienopirimidina como inibidores de nik | |
| BR112017008039A2 (pt) | derivados de pirazol como inibidores de nik | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| BR112015026257A2 (pt) | terapia de combinação compreendendo um composto di-hidropirazino-pirazina e um antagonista do receptor de andrógeno para tratar câncer de próstata |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |